文献速递胸部肿瘤

染色体15q15缺失驱动非小细胞肺癌脑转移

Chromosome 15q15 Deletion Drives Brain Metastasis in NSCLC.
PubMed 文献 · J Thorac Oncol · 2025-11-07

该研究通过三个独立亚洲NSCLC队列(全基因组/全外显子测序及配对脑转移样本)发现,15q15缺失在发生脑转移的原发瘤中显著富集,与EGFR突变共存,且独立增加脑转移累积发生率而不影响其他器官转移。缺失区域包含MGA基因,转录组显示MYC信号和OXPHOS激活,15q15缺失细胞系对OXPHOS抑制剂elesclomol敏感。

要点

  • 15q15缺失在脑转移患者原发瘤中富集(73% vs 39%,p=0.004),增加脑转移风险(SHR=3.9,p=0.008)。
  • 15q15缺失与EGFR突变显著共存(p=2.8×10-7),配对脑转移灶中46.7%仅见于转移灶。
  • 缺失区域含MGA基因,MYC信号和OXPHOS激活,缺失细胞系对elesclomol敏感。

核心结论

  • 15q15缺失通过异常MYC信号及碳水化合物代谢重编程促进NSCLC脑转移。

研究设计与样本

  • 分析三个独立亚洲NSCLC切除队列:发现队列180例原发瘤行WGS,验证队列901例原发瘤行WES,脑转移队列8例脑转移样本及17对配对原发-脑转移样本行WGS。
  • 验证队列中172例样本行RNA测序,并使用NSCLC细胞系进行药物敏感性分析。

主要发现

  • 发现队列中,15q15缺失在脑转移患者原发瘤中比例高于无缺失者(73% vs 39%,p=0.004)。
  • Fine-Gray竞争风险分析显示,15q15缺失原发瘤的脑转移累积发生率显著更高(SHR=3.9,p=0.008),其他器官转移无显著差异。
  • 15q15缺失与EGFR突变显著共存(p=2.8×10-7)。
  • 配对原发-脑转移样本中,46.7%患者15q15缺失仅见于脑转移灶。
  • 缺失区域包含MGA基因(MYC信号抑制因子),转录组分析显示脑转移患者原发瘤中MYC信号和OXPHOS激活。

关键数值与推荐

  • 15q15缺失在脑转移患者原发瘤中富集(73% vs 39%,p=0.004)。
  • 15q15缺失增加脑转移累积发生率(SHR=3.9,p=0.008)。
  • 15q15缺失与EGFR突变共存(p=2.8×10-7)。
  • 配对样本中46.7%患者15q15缺失仅见于脑转移灶。
  • 携带15q15缺失的NSCLC细胞系对OXPHOS抑制剂elesclomol选择性敏感。

临床怎么用

  • 对NSCLC原发瘤检测15q15缺失可能有助于识别脑转移高风险患者,尤其是EGFR突变者。
  • 15q15缺失及MYC/OXPHOS激活提示OXPHOS抑制剂(如elesclomol)作为潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Brain metastasis (BM) is a devastating complication of NSCLC, particularly in NSCLC tumors harboring EGFR mutations. However, the genomic alterations driving BM remain poorly understood. METHODS: We analyzed three independent cohorts of resected NSCLCs from Asian patients, including 1081 primary tumor (PT) samples analyzed by whole-genome sequencing (WGS, discovery cohort, n = 180) or whole-exome sequencing (WES, validation cohort, n = 901), eight BM samples, and 17 matched primary-BM pairs analyzed by WGS (BM cohort). Furthermore, RNA sequencing of the available 172 samples in the validation cohort and drug sensitivity profiling using NSCLC cell lines were performed. RESULTS: In the discovery cohort, deletions of the 15q15 chromosomal segment were more enriched in PTs from patients with BM than in those without this deletion (73% versus 39%, p = 0.004). Cumulative BM incidence was significantly higher in PTs with the 15q15 deletion (subdistribution hazard ratio = 3.9, p = 0.008 [Fine-Gray competing risk analysis]), whereas metastases at other organ sites did not differ significantly. These findings were obtained using the validation cohort. The 15q15 deletions significantly co-occurred with EGFR mutations (p = 2.8 × 10-7). In matched PT-BM pairs, the 15q15 deletion was detected exclusively in BMs in 46.7% of patients. The deleted region includes the MGA gene, encoding a suppressor of MYC signaling. Transcriptomic analysis revealed MYC signaling and oxidative phosphorylation (OXPHOS) activation in PTs from patients with BM. NSCLC cell lines harboring the 15q15 deletion were selectively sensitive to elesclomol, an OXPHOS inhibitor. CONCLUSIONS: The 15q15 deletion promotes BM development through aberrant MYC signaling and the subsequent reprogramming of carbohydrate metabolism.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Miyakoshi J, Shiraishi K, Mochizuki A, et al. Chromosome 15q15 Deletion Drives Brain Metastasis in NSCLC. J Thorac Oncol. 2025. PMID: 41207477. doi:10.1016/j.jtho.2025.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。